Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma
Entidad
UAM. Departamento de MedicinaEditor
Lippincott Williams and Wilkins Ltd.Fecha de edición
2021-04-01Cita
10.1097/RLU.0000000000003512
Clinical Nuclear Medicine 46.4 (2021): 310-322
ISSN
0363-9762 (print); 1536-0229 (online)DOI
10.1097/RLU.0000000000003512Financiado por
None declaredMaterias
F-FDG PET/CT; MR; multiple myeloma; skeletal survey; MedicinaDerechos
© 2021 The Author(s)Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Resumen
PURPOSE: To compare the agreement between whole-body (WB) magnetic resonance (MR) imaging, 18F-FDG PET/CT, and skeletal survey (SS) in patients with multiple myeloma (MM) for diagnosis, initial staging, response evaluation, and early detection of complications. METHODS: This is a retrospective cohort study including MM patients who were diagnosed, treated, and followed in 2 institutions. These patients were studied with SS, WB-MR, and/or 18F-FDG PET/CT. We studied bone lesions by anatomical locations and analyzed the concordance between SS and a tomographic technique (WB-MR or 18F-FDG PET/CT) and between both tomographic techniques (WB-MR and PET/CT). RESULTS: Forty-four MM patients with a mean age of 62.6 years (range, 38-85 years) were included from January 2012 to February 2016. Whole-body MR and 18F-FDG PET/CT found more lesions than SS in every location except in the skull. Concordance between WB-MR and 18F-FDG PET/CT was either good or excellent in most of the locations and in plasmacytoma studies. However, WB-MR was better than 18F-FDG PET/CT in the study of complications (medullar compression and vascular necrosis). CONCLUSIONS: Our results suggest the study of MM patients should include WB-MR and/or 18F-FDG PET/CT, whereas SS is only useful for the skull. Whole-body MR and 18F-FDG PET/CT are complementary techniques, because both of them show good concordance in almost every location. It is still necessary to individualize the indication of each technique according to patient characteristics.
Lista de ficheros
Google Scholar:Gómez León, M. de las Nieves
-
Aguado Bueno, Beatriz
-
Herreros Pérez, María
-
León Ramírez, Luisa F.
-
Alegre Amor, Adrián
-
Colletti, Patrick M.
-
Rubello, Domenico
-
Carreras, José L.
-
Delgado Bolton, Roberto C.
Lista de colecciones del ítem
Registros relacionados
Mostrando ítems relacionados por título, autor, creador y materia.
-
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
San Miguel, Jesús F.; Weisel, Katja C.; Song, Kevin W.; Delforge, Michel; Karlin; Lionel; Goldschmidt, Hartmut; Moreau, Philippe; Banos, Anne; Oriol, Albert; Garderet, Laurent; Cavo, Michele; Ivanova, Valentina; Alegre Amor, Adrián; Martínez-López, Joaquín; Chen, Chritine; Renner, Christoph; Bahlis, Nizar Jacques; Yu, Xin; Teasdale, Terri; Sternas, Lars; Jacques, Christian; Zaki, Mohamed H.; Dimopoulos, Meletios A.
2015-01-01 -
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Dimopoulos, Meletios A.; Weise, Katja C.; Song, Kevin W.; Delforge, Michel; Karlin, Lionel; Goldschmidt, Hartmut; Moreau, Philippe; Banos, Anne; Oriol, Albert; Garderet, Laurent; Cavo, Michele; Ivanova, Valentina; Alegre Amor, Adrián; Martínez-López, Joaquín; Chen, Christine; Spencer, Andrew; Knop, Stefan; Bahlis, Nizar J.; Renner, Christoph; Yu, Xin; Hong, Kevin; Sternas, Lars; Jacques, Christian; Zaki, Mohamed H.; San Miguel, Jesús F.
2015-01-01